芬蘭Aqsens Health公司及其中國合作伙伴歐際醫(yī)藥已獲得在中國江蘇省開展的一項前列腺癌和膀胱癌的臨床前研究項目的資助。

      芬蘭圖爾庫。Aqsens Health很高興宣布與總部位于中國南京的歐際醫(yī)藥合作開展一個新的臨床前研究項目。該合作研究計劃于2024年在中國江蘇省進行前列腺癌和膀胱癌的臨床前試驗。這項研究將推進Aqsens Health的增強型時間分辨熒光（E-TRF）方法和生物傳感器的開發(fā)，目的是提高從尿液中早期檢測前列腺癌和膀胱癌的能力。

      南京的這項合作研究建立在Aqsens在芬蘭對前列腺癌和膀胱癌檢測的廣泛研究基礎(chǔ)上，還結(jié)合了Aqsens與芬蘭圖爾庫大學(xué)醫(yī)院合作的轉(zhuǎn)移性癌癥研究項目的領(lǐng)先實踐。該研究項目計劃將持續(xù)到2024年底。

       合作的第一階段將側(cè)重于前列腺癌的臨床前試驗，目的是為申請臨床試驗許可開展基礎(chǔ)研究。前列腺癌試驗之后將進行膀胱癌研究。該試驗將與江蘇省腫瘤醫(yī)院和腫瘤專家合作進行，該項研究將為Aqsens獲得大規(guī)模臨床試驗許可提供支撐，并在未來中國市場上開展Aqsens Health在前列腺癌和膀胱癌診斷領(lǐng)域的注冊許可。

       歐際醫(yī)藥的一個研究團隊將接受在Aqsens實驗室開發(fā)體系中使用E-TRF和生物傳感器的技術(shù)培訓(xùn)，Aqsens實驗室的開發(fā)體系專門用于開發(fā)Aqsens Health的生物傳感器、運行E-TRF與生物傳感器分析以及培訓(xùn)研究人員。培訓(xùn)將分兩步進行，首先是在線培訓(xùn)，然后在芬蘭圖爾庫的Aqsens Health實驗室進行實踐培訓(xùn)。認證合格后，歐際醫(yī)藥的研究團隊將能夠在Aqsens Health科學(xué)團隊的支持下在中國進行復(fù)雜的研究工作。

      歐際醫(yī)藥首席執(zhí)行官趙萬洲博士表示：“我們很高興能與Aqsens Health合作，采用Aqsens Health的E-TRF和生物傳感器技術(shù)，建立創(chuàng)新手段來篩查泌尿系統(tǒng)癌癥和潛在的其他疾病。”

      趙博士還表示：“通過這種合作，我們將有效推進健康行動，從而在中國惡性腫瘤預(yù)防領(lǐng)域發(fā)揮一定的影響”。

      Aqsens Health的首席執(zhí)行官Timo Teimonen表示：“無創(chuàng)采樣檢測具有許多優(yōu)勢，如發(fā)現(xiàn)新的生物標志物的可能性及效率大幅提高，研發(fā)成本大幅降低，中國對我們的E-TRF和生物傳感器表現(xiàn)出了濃厚的興趣，這些傳感器專門設(shè)計用于分析無創(chuàng)生物樣本。這是Aqsens Health邁出的重要一步，因為它使我們能夠接觸世界最大的單一市場?！?/span>

有關(guān)詳細信息，請聯(lián)系：

首席執(zhí)行官兼聯(lián)合創(chuàng)始人

Timo Tei monen

+358 40 5853105 | timo.tei monen@aqsens.com

關(guān)于：

Aqsens Health Oy是一家芬蘭醫(yī)療科技公司，開發(fā)針對高影響疾病的非侵入性篩查測試。該公司的研究項目側(cè)重于開發(fā)適合發(fā)展中經(jīng)濟體需求的基于唾液的傳染病檢測方法，并建立了準確且經(jīng)濟高效的泌尿系統(tǒng)腫瘤的篩查方法。這些測試使用了Aqusens Health的新型E-TRF方法和噬菌體生物傳感器相結(jié)合的技術(shù)系統(tǒng)。

歐際醫(yī)藥是一家專注于醫(yī)藥創(chuàng)新和生物科學(xué)技術(shù)的公司。歐際醫(yī)藥的研究由來自不同領(lǐng)域的優(yōu)秀國際科學(xué)家團隊領(lǐng)導(dǎo)，該公司在中國江蘇省獲得了多項創(chuàng)業(yè)榮譽。歐際醫(yī)藥總部位于中國南京，與中國的多家醫(yī)療機構(gòu)有著廣泛深入的合作關(guān)系。

詳情鏈接：

https://www.aqsens.com/news-and-blog/aqsens-health-og-pharma-collaboration

Aqsens Health starting pre-clinical trialsfor urinary tract cancer detection in China

Aqsens Health and its Chinese partner OG Pharmaceuticals have received funding for ajoint prostate and bladder cancer pre-clinical and clinical research project in Jiangsu Province in China.

Turku, Finland. Aqsens Health is happy to announce a new preclinical and clinical research project with OG pharmaceuticals, based in Nanjing, China. The research partnership aims to perform prostate and bladder cancer pre-clinical trials in Jiangsu Province in 2024. The study will advance  Aqsens  Health’s  E-TRF  method  and  biosensor  development  with  a  goal  to improve the early detection of prostate and bladder cancers from urine.

This research collaboration in Nanjing builds upon Aqsens' extensive research on prostate and bladder cancer detection in Finland and it also incorporates leading practices derived from Aqsens’ research  project on metastatic cancer in partnership with Turku University Hospital. The project is planned to last until the end of 2024.

The ? rst phase of the collaboration will focus on pre-clinical trials for prostate cancer with the aim to apply for permission to perform clinical trials. The prostate cancer trial will be followed by a bladder cancer study. The trials will be conducted in collaboration with Jiangsu Cancer Hospital and expert oncologists, and will enable Aqsens to obtain the permission for a large-scale clinical trial and the certi?cation of Aqsens Health’s AQ Prostate and AQ Bladder in the Chinese market.

A research team from OG Pharmaceuticals will be trained to use E-TRF and biosensor with the AQ Lab  development  environment,  which  was  purposely  built  to  be  used  in  developing Aqsens Health’s biosensors, running E-TRF and biosensor analyses, and training research personnel. The training will be conducted in two steps, ? rst online and then physically at Aqsens  Health’s  laboratories  in  Turku.  After  certi?cation  the  researchers  will  be  able  to conduct complex research work in China under the supervision of Aqsens Health’s scienti?c team.

OG Pharma quote

“We are  excited to  collaborate with Aqsens  Health  to  build  innovative  means  to screen urinary tract cancers and potentially other diseases as well using their E-TRF and biosensor technology,” says OG Pharmaceuticals CEO, Dr. Wanzhou Zhao.

“With this  collaboration  we  can  be  a  part  of  something  that  can  have  an  impact  on preventive health actions in China,” Dr. Zhao continues.

“ Non-invasive sampling   has  many  advantages,  like  the  possibility  of  discovering  new complementary  biomarkers  and  superior  cost  ef?ciency,  and  China  has  shown  strong interest  towards  our   E-TRF  and  biosensors  which  are  speci?cally  designed  to  analyze non-invasive, biological samples. This is an important step for Aqsens Health as it gives us access to the world's largest single market,“ concludes Aqsens Health’s CEO Timo Tei monen.

For more information, contact:

CEO and Co-Founder

Timo Tei monen

+358 40 5853105 | timo.tei monen@aqsens.com

About:

Aqsens Health  Oy  is  a  Finnish  med tech  startup  developing  non-invasive  screening  tests  for high-impact diseases. The company’s research projects focus on developing saliva-based infectious disease  detection  ?t  for  the  needs of  developing  economies,  and  establishing an  accurate  and cost-ef?cient urine-based screening test for urinary tract cancers. The tests use Aqsens Health’s novel E-TRF method in combination with phage-biosensors.

Nanjing OG  Pharmaceuticals  Ltd.  is  a  company  focused  on  pharmaceutical   innovations  and bioscience  technologies.  OG  P harma’s  research  is  led  by an  accomplished  international team of scientists from various ?e lds, and the company has been awarded several entrepreneurial honors in Jiangsu  Province.  OG   P harma  is  based  in  Nanjing, just  north of  Shanghai,  and works  in  broad connection with hospitals in China.